脂蛋白 (a) 和脑血管支架植入后的复发性缺血事件之间的相关性
概括
升高的脂蛋白a (Lp[a]) 水平显著增加了脑内或脑外动脉支架患者复发性缺血事件的风险. 这一发现突出显示了Lp[a]作为一种关键的预测器,可以预测造后的不良结果.
科学领域:
- 心血管医学 心血管医学
- 神经学 神经学
- 临床研究 临床研究
背景情况:
- 脂蛋白 (Lp[a]) 在支架后复发性缺血事件中的作用尚未完全理解.
- 调查Lp[a]对于管理动脉支架患者至关重要.
研究的目的:
- 在接受动脉支架的患者中确定升高的Lp(a) 水平和缺血事件之间的关联.
- 确定Lp(a]) 作为该患者队列中的潜在风险因素.
主要方法:
- 分析了一组553名接受内或外动脉支架的患者.
- 考克斯回归和名图模型被用于评估Lp (a) 影响和预测结果.
- 术后缺血事件被仔细跟踪.
主要成果:
- 19.3%的患者经历了缺血的结果,在升高的Lp(a) 组 (>30 mg/dL) 中的比率更高.
- 升高的Lp (a) 与缺血事件的可能性增加了1.811倍.
- 每增加1 mg/dL的Lp (a) 与复发风险增加1.008倍相关.
结论:
- 脂蛋白 (a) 升高是支架患者缺血事件的重要独立风险因素.
- 在接受动脉支架的患者的风险分层中,应考虑Lp (a) 水平.
- 进一步的研究可能会探索针对升高的Lp的向治疗方法,以预防复发事件.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.3K
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.4K
相关概念视频
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Coronary Artery Disease IV: Preventive Measures
893
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
893
Coronary Artery Disease V: Interprofessional Care
452
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
452
Acute Coronary Syndrome III: Diagnostic Studies
502
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
502
Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Atherosclerosis III: Management
747
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747
